Cellectar Biosciences Inc
CLRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.22M
Close$
$4.90
183.4% upside
Current Fair Value
183.4% upsideUndervalued by 183.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.22 Million |
|---|---|
| Enterprise Value | $-18,240,210.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.35 |
| Beta | 0.56 |
| Outstanding Shares | 12,231,851 |
Return
| Return on Equity | -74.73% |
|---|---|
| Return on Assets | -60.93% |
| Return on Invested Capital | -74.26% |
Valuation & Multiples
| P/E Ratio | -0.39 |
|---|---|
| PEG | -1.43 |
| Price to Sales | - |
| Price to Book Ratio | 0.87 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.78 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.08 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$12.00 M
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.57
Average shareholder expectationRevenue Estimate
$17.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 26.65%▲ 19.32% |
|---|---|
| Total Invested | $9.08M▲ 1017.00% |
| Investors Holding | 29▲ 10.00% |
ESG Score
No data
About Cellectar Biosciences Inc
CEO: James Caruso